Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Emtricitabine / tenofovir DF (Truvada®) is recommended for use within NHS Wales as an option for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults who are treatment-naïve and in line with current BHIVA guidelines. It should only be prescribed by HIV specialists. |
||
|
||
Medicine details |
||
| Medicine name | emtricitabine/tenofovir (Truvada®) | |
| Formulation | film-coated tablet | |
| Reference number | 123 | |
| Indication | Antiretroviral combination therapy for the treatment of HIV-1 infected adults aged 18 years and over |
|
| Company | Gilead Sciences Ltd | |
| BNF chapter | Infections | |
| Assessment type | Full | |
| Status | Recommended | |
| Advice number | 0507 | |
| NMG meeting date | 17/05/2007 | |
| AWMSG meeting date | 12/06/2007 | |
| Ratification by Welsh Government | 30/07/2007 | |
| Date of issue | 10/08/2007 | |